Patient data by unique patient number
| UPN . | Age/sex . | Cytogenetics FLT3-ITD . | Risk group . | Remission analysis . | Expanded analysis . | Event . | Outcome . | IL-6 level (pg/mL) . |
|---|---|---|---|---|---|---|---|---|
| 1 | 6.0/F | t(9;11) | LR | Y | Y | Censored | A | 6.34 |
| 2 | 0.76/F | Normal | HR | N | Y | Relapse | DD | 133.46 |
| 3 | 11.2/F | t(8;21) | LR | N | Y | Relapse | DD | 88.62 |
| 4 | 17.0/F | 4+ | LR | N | N | Censored | A | 3.22 |
| 5 | 0.55/F | t(2;11) | LR | Y | N | Relapse | TD | 71.3 |
| 6 | 0.70/F | ND | LR | N | Y | Relapse | DD | 41.36 |
| 7 | 11.2/M | Normal | HR | N | Y | Refractory | DD | 1.59 |
| 8 | 14.9/M | t(6;9) | HR | N | Y | Censored | A | 8369 |
| 9 | 1.5/F | Complex | LR | N | Y | Relapse | DD | 12.23 |
| 10 | 10.4/M | 13q− | HR | N | Y | Censored | A | 62.21 |
| 11 | 11.1/M | t(9;11) | LR | Y | Y | Censored | A | 15.51 |
| 12 | 7.7/M | t(8;21) | LR | Y | Y | Relapse | TD | 47.97 |
| 13 | 9.7/M | t(1;6;11) | HR | N | Y | Relapse | DD | 6.26 |
| 14 | 3.4/F | t(8;21) | LR | Y | N | Censored | A | 465.47 |
| 15 | 13.3/M | t(10;11) | HR | N | N | Refractory | DD | 19.42 |
| 16 | 14.1/F | t(9;11) | LR | Y | Y | Censored | A | 3.31 |
| 17 | 12.5/M | −7 | HR | N | N | Relapse | A | <3 |
| 18 | 4.8/F | t(8;21) | LR | N | Y | Censored | A | 11.88 |
| 19 | 1.8/F | Tetraploid | LR | N | N | Relapse | A | 13.8 |
| 20 | 3.7/F | 11q23 del | LR | N | N | Relapse | A | 6.62 |
| 21 | 0.6/F | t(1;11) | LR | Y | N | Censored | A | 11.79 |
| 22 | 0.4/F | 11q23 del, FLT3-ITD | HR | N | N | Relapse | DD | 13.08 |
| 23 | 12.4/M | Normal | HR | N | N | Relapse | DD | 4.55 |
| 24 | 8.3/M | −7 | HR | Y | Y | DIR | TD | 10.66 |
| 25 | 14.9/M | t(8;21) | LR | Y | Y | Relapse | DD | 34.45 |
| 26 | 4.4/M | FLT3-ITD | HR | N | N | Relapse | DD | 38.83 |
| 27 | 9.7/M | inv(16) | LR | Y | N | Censored | A | 5.15 |
| 28 | 7.1/M | t(8;21) | LR | N | N | Censored | A | 41.81 |
| 29 | 9.7/M | Normal | HR | N | N | Relapse | DD | 4.86 |
| 30 | 14.0/M | inv(16) | LR | Y | N | Relapse | A | 12059 |
| 31 | 0.4/F | t(10;11) | HR | N | N | Censored | A | 4.4 |
| 32 | 8.5/M | inv(16), 7q− | LR | Y | N | Relapse | A | 3.77 |
| 33 | 0.8/M | inv(16) | LR | Y | Y | Censored | A | 3.15 |
| 34 | 12.7/F | Complex | LR | Y | Y | Censored | A | 10.42 |
| 35 | 3.0/M | t(8;21) | LR | Y | Y | Censored | A | 4.78 |
| 36 | 14.3/F | inv(16) | LR | Y | N | Censored | A | 4.7 |
| 37 | 3.3/M | Normal | LR | Y | N | Relapse | DD | 28.12 |
| 38 | 2.1/F | +8, +21 | LR | Y | N | Censored | A | 4.42 |
| 39 | 1.3/F | Complex, t(10;11) | HR | Y | Y | Censored | A | 52.27 |
| 40 | 16.6/F | t(6;11) | HR | N | N | Relapse | DD | <3 |
| 41 | 17.3/M | Derivative 8 | LR | Y | Y | Relapse | A | 26.96 |
| 42 | 1.3/M | t(10;11) | HR | Y | N | Censored | A | 40.12 |
| 43 | 13.6/F | 8+ | HR | N | N | Relapse | DD | 3.19 |
| 44 | 0.6/F | t(11;15) | LR | Y | N | Censored | A | 6.93 |
| 45 | 17.7/M | 13q− | HR | N | N | Relapse | A | 6.86 |
| NBM1 | 5.8/F | — | — | — | Y | — | — | 2.62 |
| NBM2 | 12.2/M | — | — | — | — | — | — | <1.7 |
| NBM3 | 9.2/F | — | — | — | — | — | — | 4.54 |
| NBM4 | 3.1/F | — | — | — | Y | — | — | <1.53 |
| NBM5 | 13.0/M | — | — | — | Y | — | — | <1.7 |
| NBM6 | 6.7/M | — | — | — | Y | — | — | 5.67 |
| NBM7 | 4.8/M | — | — | — | Y | — | — | <1.53 |
| UPN . | Age/sex . | Cytogenetics FLT3-ITD . | Risk group . | Remission analysis . | Expanded analysis . | Event . | Outcome . | IL-6 level (pg/mL) . |
|---|---|---|---|---|---|---|---|---|
| 1 | 6.0/F | t(9;11) | LR | Y | Y | Censored | A | 6.34 |
| 2 | 0.76/F | Normal | HR | N | Y | Relapse | DD | 133.46 |
| 3 | 11.2/F | t(8;21) | LR | N | Y | Relapse | DD | 88.62 |
| 4 | 17.0/F | 4+ | LR | N | N | Censored | A | 3.22 |
| 5 | 0.55/F | t(2;11) | LR | Y | N | Relapse | TD | 71.3 |
| 6 | 0.70/F | ND | LR | N | Y | Relapse | DD | 41.36 |
| 7 | 11.2/M | Normal | HR | N | Y | Refractory | DD | 1.59 |
| 8 | 14.9/M | t(6;9) | HR | N | Y | Censored | A | 8369 |
| 9 | 1.5/F | Complex | LR | N | Y | Relapse | DD | 12.23 |
| 10 | 10.4/M | 13q− | HR | N | Y | Censored | A | 62.21 |
| 11 | 11.1/M | t(9;11) | LR | Y | Y | Censored | A | 15.51 |
| 12 | 7.7/M | t(8;21) | LR | Y | Y | Relapse | TD | 47.97 |
| 13 | 9.7/M | t(1;6;11) | HR | N | Y | Relapse | DD | 6.26 |
| 14 | 3.4/F | t(8;21) | LR | Y | N | Censored | A | 465.47 |
| 15 | 13.3/M | t(10;11) | HR | N | N | Refractory | DD | 19.42 |
| 16 | 14.1/F | t(9;11) | LR | Y | Y | Censored | A | 3.31 |
| 17 | 12.5/M | −7 | HR | N | N | Relapse | A | <3 |
| 18 | 4.8/F | t(8;21) | LR | N | Y | Censored | A | 11.88 |
| 19 | 1.8/F | Tetraploid | LR | N | N | Relapse | A | 13.8 |
| 20 | 3.7/F | 11q23 del | LR | N | N | Relapse | A | 6.62 |
| 21 | 0.6/F | t(1;11) | LR | Y | N | Censored | A | 11.79 |
| 22 | 0.4/F | 11q23 del, FLT3-ITD | HR | N | N | Relapse | DD | 13.08 |
| 23 | 12.4/M | Normal | HR | N | N | Relapse | DD | 4.55 |
| 24 | 8.3/M | −7 | HR | Y | Y | DIR | TD | 10.66 |
| 25 | 14.9/M | t(8;21) | LR | Y | Y | Relapse | DD | 34.45 |
| 26 | 4.4/M | FLT3-ITD | HR | N | N | Relapse | DD | 38.83 |
| 27 | 9.7/M | inv(16) | LR | Y | N | Censored | A | 5.15 |
| 28 | 7.1/M | t(8;21) | LR | N | N | Censored | A | 41.81 |
| 29 | 9.7/M | Normal | HR | N | N | Relapse | DD | 4.86 |
| 30 | 14.0/M | inv(16) | LR | Y | N | Relapse | A | 12059 |
| 31 | 0.4/F | t(10;11) | HR | N | N | Censored | A | 4.4 |
| 32 | 8.5/M | inv(16), 7q− | LR | Y | N | Relapse | A | 3.77 |
| 33 | 0.8/M | inv(16) | LR | Y | Y | Censored | A | 3.15 |
| 34 | 12.7/F | Complex | LR | Y | Y | Censored | A | 10.42 |
| 35 | 3.0/M | t(8;21) | LR | Y | Y | Censored | A | 4.78 |
| 36 | 14.3/F | inv(16) | LR | Y | N | Censored | A | 4.7 |
| 37 | 3.3/M | Normal | LR | Y | N | Relapse | DD | 28.12 |
| 38 | 2.1/F | +8, +21 | LR | Y | N | Censored | A | 4.42 |
| 39 | 1.3/F | Complex, t(10;11) | HR | Y | Y | Censored | A | 52.27 |
| 40 | 16.6/F | t(6;11) | HR | N | N | Relapse | DD | <3 |
| 41 | 17.3/M | Derivative 8 | LR | Y | Y | Relapse | A | 26.96 |
| 42 | 1.3/M | t(10;11) | HR | Y | N | Censored | A | 40.12 |
| 43 | 13.6/F | 8+ | HR | N | N | Relapse | DD | 3.19 |
| 44 | 0.6/F | t(11;15) | LR | Y | N | Censored | A | 6.93 |
| 45 | 17.7/M | 13q− | HR | N | N | Relapse | A | 6.86 |
| NBM1 | 5.8/F | — | — | — | Y | — | — | 2.62 |
| NBM2 | 12.2/M | — | — | — | — | — | — | <1.7 |
| NBM3 | 9.2/F | — | — | — | — | — | — | 4.54 |
| NBM4 | 3.1/F | — | — | — | Y | — | — | <1.53 |
| NBM5 | 13.0/M | — | — | — | Y | — | — | <1.7 |
| NBM6 | 6.7/M | — | — | — | Y | — | — | 5.67 |
| NBM7 | 4.8/M | — | — | — | Y | — | — | <1.53 |
Age is given in years at the time of initial diagnosis. Risk group is defined as per AAML1031 guidelines with the following additions: mixed lineage leukemia translocations identified as poor risk factors, t(6;9)(p23;q34), and myelodysplastic syndrome evolving into AML were also considered HR characteristics. Outcome column indicates status at last contact.
A, alive at time of last follow-up; DD, death due to disease; DIR, death in remission; F, female; ITD, internal tandem duplication; M, male; NBM, normal bone marrow; ND, not done; TD, death in remission due to toxicity; UPN, unique patient number.